Thermo Fisher Scientific Inc（TMO）財務資料TMOThermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. (TMO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Service, accounting for 43.0% of total sales, equivalent to $4.73B. Other significant revenue streams include Consumables and Instruments. Understanding this composition is critical for investors evaluating how TMO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Thermo Fisher Scientific Inc. maintains a gross margin of 40.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.08%, while the net margin is 14.52%. These profitability ratios, combined with a Return on Equity (ROE) of 13.50%, provide a clear picture of how effectively TMO converts its operational activities into shareholder value.

In the context of the broader market, TMO competes directly with industry leaders such as ABT and DHR. With a market capitalization of $243.30B, it holds a leading position in the sector. When comparing efficiency, TMO's gross margin of 40.70% stands against ABT's 52.49% and DHR's 57.64%. Such benchmarking helps identify whether Thermo Fisher Scientific Inc. is trading at a premium or discount relative to its financial performance.

Thermo Fisher's total revenue for Q2 2026 was $11.99 billion, with a net income of $1.74 billion, reflecting strong operational performance. The gross margin is healthy at 40.70%, indicating effective cost management.